Woodline Partners LP Has $34.58 Million Stake in Alkermes Plc (NASDAQ:ALKS)
Woodline Partners LP Has $34.58 Million Stake in Alkermes Plc (NASDAQ:ALKS)
Woodline Partners LP reduced its stake in shares of Alkermes plc (NASDAQ:ALKS – Get Rating) by 18.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,314,406 shares of the company's stock after selling 304,399 shares during the quarter. Woodline Partners LP owned approximately 0.80% of Alkermes worth $34,582,000 as of its most recent filing with the SEC.
根據伍德林合夥公司在提交給美國證券交易委員會的最新Form 13F文件中的説法,該公司在第一季度減持了18.8%的Alkermes plc股票(美國證券交易委員會代碼:ALKS-GET評級)。該公司在本季度出售了304,399股後,擁有1,314,406股公司股票。截至最近提交給美國證券交易委員會的文件,Woodline Partners LP擁有Alkermes約0.80%的股份,價值34,582,000美元。
Other institutional investors have also made changes to their positions in the company. Steward Partners Investment Advisory LLC lifted its position in Alkermes by 100.0% in the 1st quarter. Steward Partners Investment Advisory LLC now owns 1,000 shares of the company's stock worth $26,000 after buying an additional 500 shares in the last quarter. Credit Agricole S A bought a new stake in shares of Alkermes in the 4th quarter valued at approximately $35,000. UMB Bank N A MO acquired a new position in Alkermes in the fourth quarter worth approximately $47,000. Lazard Asset Management LLC bought a new position in Alkermes during the first quarter valued at approximately $72,000. Finally, Point72 Hong Kong Ltd acquired a new stake in Alkermes in the fourth quarter valued at approximately $201,000. 94.77% of the stock is currently owned by institutional investors and hedge funds.
其他機構投資者也改變了他們在該公司的頭寸。第一季度,Steward Partners Investment Consulting LLC將其在Alkermes的頭寸提高了100.0%。Steward Partners Investment Consulting LLC在上個季度又購買了500股,現在擁有1,000股該公司股票,價值26,000美元。法國農業信貸銀行在第四季度購買了Alkermes的新股份,價值約3.5萬美元。UMB Bank N A MO在第四季度收購了Alkermes的一個新頭寸,價值約47,000美元。Lazard Asset Management LLC在第一季度購買了Alkermes的一個新頭寸,價值約為72,000美元。最後,Point72 Hong Kong Ltd在第四季度收購了Alkermes的新股份,價值約201,000美元。94.77%的股票目前由機構投資者和對衝基金持有。
Alkermes Price Performance
Alkermes性價比
Shares of NASDAQ ALKS opened at $24.01 on Friday. Alkermes plc has a 12 month low of $21.24 and a 12 month high of $33.00. The business's 50 day moving average is $26.91 and its two-hundred day moving average is $27.46. The company has a quick ratio of 2.03, a current ratio of 2.39 and a debt-to-equity ratio of 0.27.
上週五,納斯達克的股價開盤報24.01美元。Alkermes plc股價跌至21.24美元的12個月低點和33.00美元的12個月高點。該業務的50日移動均線切入位在26.91美元,200日移動均線切入位在27.46美元。該公司的速動比率為2.03,流動比率為2.39,債務權益比率為0.27。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
A number of research firms have recently weighed in on ALKS. Stifel Nicolaus raised their price target on shares of Alkermes to $28.00 in a report on Wednesday, July 27th. StockNews.com downgraded shares of Alkermes from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, August 24th. Piper Sandler started coverage on Alkermes in a research report on Tuesday, August 16th. They issued a "neutral" rating and a $26.00 price target for the company. Finally, Mizuho lowered their price objective on Alkermes from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Thursday, July 28th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $30.44.
最近,許多研究公司都加入了ALKS的行列。Stifel Nicolaus在7月27日星期三的一份報告中將Alkermes的股票目標價上調至28.00美元。在8月24日週三發佈的一份研究報告中,StockNews.com將Alkermes的股票評級從“強力買入”下調至“買入”。派珀·桑德勒在8月16日星期二的一份研究報告中開始對Alkermes進行報道。他們對該公司的評級為中性,目標價為26.00美元。最後,瑞穗在7月28日(星期四)的一份報告中將Alkermes的目標價從36.00美元下調至34.00美元,並對該股設定了買入評級。五位股票研究分析師對該股的評級為持有,五位分析師對該公司股票的評級為買入。根據MarketBeat的數據,該公司目前的平均評級為“中等買入”,平均目標價為30.44美元。
Insider Buying and Selling at Alkermes
Alkermes的內幕買賣
In other Alkermes news, SVP Christian Todd Nichols sold 7,474 shares of the stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $28.26, for a total value of $211,215.24. Following the completion of the sale, the senior vice president now directly owns 21,035 shares of the company's stock, valued at approximately $594,449.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 4.76% of the company's stock.
在Alkermes的其他新聞中,高級副總裁克里斯蒂安·託德·尼科爾斯在6月21日星期二的一筆交易中出售了7,474股該公司股票。這些股票的平均價格為28.26美元,總價值為211,215.24美元。出售完成後,高級副總裁現在直接持有該公司21,035股股票,價值約594,449.10美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可以在美國證券交易委員會的網站上看到。內部人士持有該公司4.76%的股份。
About Alkermes
關於阿爾克姆斯
(Get Rating)
(獲取評級)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
Alkermes plc是一家生物製藥公司,研究、開發和商業化藥物產品,以滿足美國、愛爾蘭和國際上不同治療領域患者未得到滿足的醫療需求。其銷售的產品包括用於治療精神分裂症的肌肉注射混懸劑Aristada;用於治療酒精和防止阿片類藥物依賴的VIVITROL;用於治療精神分裂症和雙相I型障礙的Risperdal Consta;用於治療精神分裂症和分裂情感障礙的INVEGA SUSTENNA;用於治療精神分裂症和分裂情感障礙的XEPLION、INVEGA TRINZA和TREVICTA;以及用於治療成人復發形式的多發性硬化症的VUMERITY,包括臨牀孤立綜合徵、復發緩解和活躍的繼發性進行性疾病。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Alkermes (ALKS)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免費獲取StockNews.com關於Alkermes的研究報告(ALKS)
- MarketBeat:回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦,這些股票可能表現優異
- DocuSign是否即將發生重大逆轉?
- 石油和天然氣股票:投資可再生能源的安全途徑
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.
接受Alkermes Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Alkermes和相關公司的最新新聞和分析師評級的每日簡要摘要。